文献速递产科母胎医学

SMFM特别声明:多胎妊娠的科学现状:独特考虑与重要性

SMFM Special Statement: State of the science on multifetal gestations: unique considerations and importance.
PubMed 文献 · Am J Obstet Gynecol · 2019-04-16

本文通过检索2012-2016年PubMed的III期和IV期随机对照试验,分析多胎妊娠在四大产科并发症研究中的代表性。226项研究中,早产研究对多胎妊娠代表性最高(17%同时招募单胎和多胎,18%仅招募多胎),而子痫前期、胎儿生长受限和妊娠期糖尿病研究中多胎代表性分别为17%、8%和2%,且无研究仅限多胎妊娠。文章还讨论了多胎妊娠独特的病理生理、研究设计挑战及证据缺口。

要点

  • 早产研究对多胎妊娠代表性最高,17%试验同时招募单胎和多胎,18%仅招募多胎。
  • 子痫前期、胎儿生长受限和妊娠期糖尿病研究中,分别有17%、8%和2%的试验同时招募单胎和多胎。
  • 双胎生长从约32周开始偏离单胎,但区分病理性和生理性生长偏离需长期随访研究。

核心结论

  • 多胎妊娠常被研究排除,但其对围产期发病率、死亡率和医疗费用的贡献不成比例。
  • 在主要针对单胎妊娠的研究中考虑纳入多胎妊娠很重要,即使样本量不足,以便汇总小型研究结果时获得多胎妊娠特有的见解。
  • 多胎妊娠孕妇的临床管理面临独特挑战,常见产科问题的诊断和治疗缺乏明确的循证依据。

研究设计与样本

  • 通过PubMed检索2012-2016年期间限定为III期和IV期随机对照试验、英文撰写、涉及至少1种主要妊娠并发症(胎儿生长受限或小于胎龄儿、妊娠期糖尿病、子痫前期、早产)的研究。
  • 共纳入226项研究进行分析。

主要发现

  • 226项研究中,早产研究对多胎妊娠代表性最高:17%的试验同时招募单胎和多胎妊娠,另18%的试验仅招募多胎妊娠。
  • 子痫前期、胎儿生长受限和妊娠期糖尿病研究中,分别有17%、8%和2%的试验同时招募单胎和多胎妊娠;这3个主题均无试验仅限多胎妊娠孕妇。
  • 双胎生长从约32周妊娠开始偏离单胎生长;需要长期随访研究以更好区分病理性和生理性生长偏离,包括双胎(或更多胎)间的生长不一致。
  • 妊娠期糖尿病或子痫前期几乎没有专门针对双胎的临床试验,现有试验中多胎妊娠亚组样本量不足以得出明确结论。

临床怎么用

  • 短宫颈(20多年前确立)仍是双胎早产的最佳单一预测指标。
  • 多胎妊娠独特的病理生理包括胎盘过多、胎盘拥挤或子宫胎盘单元无法支持多胎胎儿正常生长、胎盘植入部位不理想导致胎盘位置异常风险增加。
  • 多胎妊娠的其他不良结局受双胎特有危险因素影响,尤其是绒毛膜性。

局限性

  • 早产研究未能识别充分的预测性检测、建立有效干预措施并区分双胎早产的潜在病理生理。
  • 胎儿生长问题仍存:双胎生长从约32周开始偏离单胎,但区分病理性和生理性生长偏离需长期随访研究。
  • 妊娠期糖尿病或子痫前期几乎没有专门针对双胎的临床试验,现有试验中多胎妊娠亚组样本量不足以得出明确结论。
  • 确定适当孕妇营养或微量营养素补充以优化妊娠和儿童健康是另一个重要领域。
  • 多胎妊娠研究设计需考虑独特方面,如产前和分娩时正确胎儿的指定和追踪,以及必须使用正确统计方法处理相关数据,因为多个胎儿共享同一母亲和宫内环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We sought to review the state of the science for research on multiple gestations. A literature search was performed with the use of PubMed for studies to quantify the representation of multiple gestations for a sample period (2012-2016) that were limited to phase III and IV randomized controlled trials, that were written in English, and that addressed at least 1 of 4 major pregnancy complications: fetal growth restriction or small-for-gestational-age fetus, gestational diabetes mellitus, preeclampsia, and preterm delivery. Of the 226 studies that are included in the analysis, multiple pregnancies were most represented in studies of preterm delivery: 17% of trials recruited both singleton and multiple pregnancies; another 18% of trials recruited only multiple pregnancies. For trials that studied preeclampsia, fetal growth restriction, and gestational diabetes mellitus, 17%, 8%, and 2%, respectively, recruited both singleton and multiple gestations. None of the trials on these 3 topics were limited to women with a multiple pregnancy. Women with a multiple pregnancy are at risk for complications similar to those of women with singleton pregnancies, but their risk is usually higher. Also, the pathophysiologic condition for some complications differs in multiple gestations from those that occur in singleton gestations. Conditions that are unique to multiple pregnancies include excess placenta, placental crowding or inability of the uteroplacental unit to support the normal growth of multiple fetuses, or suboptimal placental implantation sites with an increased risk of abnormal placental location. Other adverse outcomes in multiple gestations are also influenced by twin-specific risk factors, most notably chorionicity. Although twins have been well represented in many studies of preterm birth, these studies have failed to identify adequate predictive tests (short cervical length established over 2 decades ago remains the single best predictor), to establish effective interventions, and to differentiate the underlying pathophysiologic condition of twin preterm birth. Questions about fetal growth also remain. Twin growth deviates from that of singleton gestations starting at approximately 32 weeks of gestation; however, research with long-term follow-up is needed to better distinguish pathologic and physiologic growth deviations, which include growth discordance among pairs (or more). There are virtually no clinical trials that are specific to twins for gestational diabetes mellitus or preeclampsia, and subgroups for multiple pregnancies in existing trials are not large enough to allow definite conclusions. Another important area is the determination of appropriate maternal nutrition or micronutrient supplementation to optimize pregnancy and child health. There are also unique aspects to consider for research design in multiple gestations, such as designation and tracking of the correct fetus prenatally and through delivery. The correct statistical methods must be used to account for correlated data because multiple fetuses share the same mother and intrauterine environment. In summary, multiple gestations often are excluded from research studies, despite a disproportionate contribution to national rates of perinatal morbidity, mortality, and health-care costs. It is important to consider the enrollment of multifetal pregnancies in studies that target mainly women with singleton gestations, even when sample size is inadequate, so that insights that are specific to multiple gestations can be obtained when results of smaller studies are pooled together. The care of pregnant women with multiple gestations presents unique challenges; unfortunately, evidence-based clinical management that includes the diagnosis and treatment of common obstetrics problems are not well-defined for this population.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Grantz KL, Kawakita T, Lu YL, et al. SMFM Special Statement: State of the science on multifetal gestations: unique considerations and importance. Am J Obstet Gynecol. 2019. PMID: 31002766. doi:10.1016/j.ajog.2019.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。